TickerFacts.

Myriad Genetics Inc (MYGN): Operating Income

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2017-06-30 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$387.20M
Year ended 2025-12-31
-$98.60M
Trailing 12 months to 2026-06-30
$274.40M2009-06-30: $126.46M2010-06-30: $135.07M2011-06-30: $157.78M2012-06-30: $180.32M2013-06-30: $228.00M2014-06-30: $274.40M2015-06-30: $133.60M2016-06-30: $153.40M2017-06-30: $44.00M2018-06-30: $121.90M2019-06-30: $7.60M2020-12-31: -$289.70M2021-12-31: -$190.50M2022-12-31: -$140.60M2023-12-31: -$257.40M2024-12-31: -$123.50M2025-12-31: -$387.20M-$387.20M
2009-06-30 Operating Income (USD) 2025-12-31
Period endedOperating IncomeChange YoYSource filing
2025-12-31-$387.20Mn/m2026-02-24, From 2025-01-01
2024-12-31-$123.50Mn/m2026-02-24, From 2024-01-01
2023-12-31-$257.40Mn/m2026-02-24, From 2023-01-01
2022-12-31-$140.60Mn/m2025-02-28, From 2022-01-01
2021-12-31-$190.50Mn/m2024-02-28, From 2021-01-01
2020-12-31-$289.70Mn/a2022-02-25, From 2020-01-01
No annual figure between 2019-06-30 and 2020-12-31.
2019-06-30$7.60M-93.8%2022-02-25, From 2018-07-01
2018-06-30$121.90M+177.0%2020-08-13, From 2017-07-01
2017-06-30$44.00Mn/c2019-08-13, From 2016-07-01
2016-06-30$153.40M+14.8%2018-08-24, From 2015-07-01
2015-06-30$133.60M-51.3%2018-08-24, From 2014-07-01
2014-06-30$274.40M+20.4%2016-08-10, From 2013-07-01
2013-06-30$228.00M+26.4%2015-08-12, From 2012-07-01
2012-06-30$180.32M+14.3%2014-08-13, From 2011-07-01
2011-06-30$157.78M+16.8%2013-08-14, From 2010-07-01
2010-06-30$135.07M+6.8%2012-08-15, From 2009-07-01
2009-06-30$126.46Mn/a2011-08-15, From 2008-07-01

Operating Income at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating IncomeChange YoY
Myriad Genetics Inc (MYGN)2025-12-31-$387.20Mn/m
Neogen Corp (NEOG)2026-05-31-$21.60Mn/m
Lantheus Holdings, Inc. (LNTH)2025-12-31$310.83M-32.0%
QuidelOrtho Corp (QDEL)2025-12-28-$919.20Mn/m
Idexx Laboratories Inc (IDXX)2025-12-31$1.36B+20.5%
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$440.99Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$16.98Mn/m
Immucell Corp (ICCC)2025-12-31$1.65Mn/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.91Mn/m

Compare MYGN, NEOG, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗